Aspen Neuroscience Secures $115M to Advance Cell Therapy
SAN DIEGO, CA — November 20, 2025 — Aspen Neuroscience, a leading developer of personalized autologous cell therapies for...
Neurodegeneration
Advertisement
FDA Clears Jupiter Neurosciences’ JOTROL™ for Phase 2a Parkinson’s Trial
JUPITER, Florida, November 5, 2025 — Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company, announced that the U.S....
FDA Grants Orphan Drug Status to Cellenkos’ CK0803 for ALS Treatment
HOUSTON, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...
Coya’s COYA 303 Shows Promise in Neuroinflammation and Treg Boost
HOUSTON, Sept. 16, 2025 – Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company specializing in regulatory T cell...
Advertisement
